Bio Special Special Report
Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpo...
December 18, 2024 | News
Analysis of Novo Holdings A/S’s Acquisition of Catalent and Novo Nordisk’s Strategic Expansion The imminent completion of ...
December 16, 2024 | Analysis
Biopharma in 2025: AI Transforming Drug Discovery and Precision Medicine The biopharma landscape in 2025 is poised for an unprecedented transformation, dr...
December 13, 2024 | Analysis
ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to treat advanced ER+/HER2- breas...
December 13, 2024 | News
87.5% of patients treated with LYNPARZA were alive at six years vs. 83.2% in the comparator arm First and only PARP inhibitor to improve survival in...
December 12, 2024 | News
The IPO class of 2024 has redefined the biopharma and life sciences landscape, marking a return to growth after a prolonged period of market caution. These...
November 27, 2024 | Report
Life Sciences CEOs bullish on growth prospects and AI investment despite economic challenges Seventy-nine percent of life sciences CEOs are conf...
November 26, 2024 | Report
Royal Philips , a global leader in health technology, has released the second set of findings from the Asia Pacific (APAC) Future Health Index (FHI) 2024 r...
November 26, 2024 | Report
Roche shared encouraging 16-week interim data from its ongoing Phase 3b/4 SALWEEN trial, revealing significant advancements in vision improvement and...
November 22, 2024 | News
Phase III MANEUVER study met primary endpoint, with an objective response rate at week 25 of 54.0% for pimicotinib versus 3.2% for placebo (p<0.0001) ...
November 21, 2024 | News
Phase III trial enrolled a total of 480 patients with moderate to severe acne-Topline results expected in the second quarter 2025 Ascletis Pharma Inc. ann...
November 13, 2024 | News
Obese or overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean ...
November 12, 2024 | News
Data from a Phase I single ascending dose (SAD) study in Australia in subjects with elevated low-density lipoprotein cholesterol (LDL-C) showed...
November 08, 2024 | News
Researchers have discovered a promising new method for potentially treating osteoarthritis (OA), a debilitating joint disease for which there are currently...
November 08, 2024 | News
Most Read
Bio Jobs
News